Receptor tyrosine kinase pathways (RTK)
Description
In this image EGFR signaling pathways are described briefly.
Anti-EGFR mAbs, tyrosine kinase inhibitors (TKI) and their inhibition mechanisms are also included.
Acknowledgements
References
Akbarzadeh Khiavi, M., Safary, A., Barar, J., Ajoolabady, A., Somi, M. H., & Omidi, Y. (2020). Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer. Cellular and molecular life sciences : CMLS, 77(6), 997–1019. https://doi.org/10.1007/s00018-019-03305-z
Chuang, D. F., & Lin, X. (2019). Targeted Therapies for the Treatment of Glioblastoma in Adults. Current oncology reports, 21(7), 61. https://doi.org/10.1007/s11912-019-0807-1
Hegi, M. E., Diserens, A. C., Bady, P., Kamoshima, Y., Kouwenhoven, M. C., Delorenzi, M., Lambiv, W. L., Hamou, M. F., Matter, M. S., Koch, A., Heppner, F. L., Yonekawa, Y., Merlo, A., Frei, K., Mariani, L., & Hofer, S. (2011). Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Molecular cancer therapeutics, 10(6), 1102–1112. https://doi.org/10.1158/1535-7163.MCT-11-0048
Nguyen, P. V., Allard-Vannier, E., Chourpa, I., & Hervé-Aubert, K. (2021). Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: Biological strategy, design and quality control. International journal of pharmaceutics, 605, 120795. https://doi.org/10.1016/j.ijpharm.2021.120795
Get started with this template for freeDon’t start from scratch.
Create professional scientific illustrations quickly and easily, even without any design expertise
- Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
- Create figures that effectively communicate your research in half the time using our editable icons.
- Use our PDB tool to quickly generate and customize protein structures
.gif)
